ACAD dropping on news of ending their drug trials of antipsychotic drug, pimavanserin, for schizophrenia

https://finance.yahoo.com/news/1-acadia-pharmaceuticals-schizophrenia-drug-204620909.html

Although not directly related to NEU, maybe the news is feeding the fear that Arcadia could struggle financially since this was their main product and perhaps impact milestone payments of Daybue.

I haven't looked in the Arcadia financials to confirm any difficulties. But I doubt this will have any impact.

Held

Bell potter has a hold on Neuren. Note this was before the trading halt before the SP rocket on 6 dec.

Given BP track record, maybe it is safe to say to ignore these recommendations but use their research to form your own thesis.

Don't want to dampen expectations, but I have a bad feeling about this trading halt

Trading halts are not usually used when results are overwhelmingly positive

Some examples where trading halts were not used for positive clinical results/approvals include:

Clarity Pharmaceuticals and the SeCURE PH2 trial update for Cohort 2 (29/11/2023   SECuRE theranostic prostate cancer trial progresses)

Telix Pharmaceuticals Receives TGA approval (02/11/2021   Australian TGA Approves Illuccix for Prostate Cancer Imaging )

Cyclopharm (02/10/2023   Cyclopharm Receives USFDA Approval for Technegas)

On the other hand for trading halts when negative news were received

Rhythm Biosciences - TGA resubmission (01/03/2023   Trading Halt , 06/03/2023   Update to TGA Submission )

Botanix - (26/09/2023   FDA Letter Requires Patient Instruction Update , 25/09/2023   Trading Halt $)

There's probably more, but these are the ones I'm tracking since I have held or held previously

Cross fingers and hope for the best on the Phase II trial results. Try not to have any expectations.

[held]